Key facts
- This page summarizes Jeffrey A. Schwaneke's Form 4/A - Amendment filing for agilon health, inc. (AGL).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Apr 2025, 19:40.
Jeffrey A. Schwaneke - 29 Nov 2023 Form 4/A - Amendment Insider Report for agilon health, inc. (AGL)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- AGL
- Reported as of
- 29 Nov 2023
- Net transaction value
- +$250,206
- SEC form
- 4/A - Amendment
- Accepted by SEC
- 03 Apr 2025, 19:40:25 UTC
- Original report date
- 30 Nov 2023
- Prior SEC filing
- 18 Apr 2023
- Next SEC filing
- 31 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mimi Yang, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
6 source fields
Reporting owner
1 detail
Key filing fact
Jeffrey A. Schwaneke filed Form 4/A - Amendment for agilon health, inc. (AGL) on 03 Apr 2025.
Change
- Previous filing in this sequence was filed on 18 Apr 2023.
- Current net transaction value: +$250,206.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AGL
transaction
Common Stock
Purchase
- Transaction value
- $250,206
- Shares
- +22,300
- Change %
- Price
- $11.22
- Shares after
- 22,300
- Date
- 29 Nov 2023
- Ownership
- By trust
- Footnotes
- F1, F2
AGL
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +428,922
- Change %
- +61%
- Price
- $0.000000
- Shares after
- 1,130,552
- Date
- 01 Apr 2025
- Ownership
- Direct
- Footnotes
- F3, F4, F5
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AGL
transaction
Derivative
Options (Right to buy)
Award
- Transaction value
- $0
- Shares
- +673,077
- Change %
- Price
- $0.000000
- Shares after
- 673,077
- Date
- 01 Apr 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 673,077
- Exercise price
- $4.08
- Footnotes
- F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $11.12 to $11.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
Footnote F2
This transaction was originally reported in November 2023 and is hereby amended to clarify that the shares were purchased by and are held in the Schwaneke Family Joint Spousal Trust.
Footnote F3
Restricted stock units that vest in three equal installments on each anniversary of April 1, 2025, subject to continued employment.
Footnote F4
Includes Performance Stock Units which may become vested subject to attainment (based on 40 trading day average closing price, exceeding twice the closing price of the Company's stock price on date of grant) and within three years from grant date.
Footnote F5
Includes restricted stock units.
Footnote F6
Options that vest in three equal installments on each anniversary of April 1, 2025, subject to continued employment.